The effect of Zingiber cassumunar (Phlai capsule) on bronchial hyperresponsiveness in asthmatic patients

Government Pharmaceutical Organization Thailand0 个研究点目标入组 30 人开始时间: 2020年3月5日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1) Patients aged 18 years or older with a diagnosis of asthma at least 1 year by allergists or pulmonologist following to GINA guideline; 2)Clinical with partly or uncontrolled symptom with using a low to medium dose inhaled corticosteroid or combination of inhaled corticosteroid / long-acting beta2-agonists (ICS/LABA) during 3 months prior to the study; 3) Asthma control test (ACT) scores 19; 4) Baseline FEV1 70% of predicted value prior to the start of the study.

•1) History of smoking more than 10 pack-years; 2) Unable to perform effective spirometry; 3)History of taking these medication during 2 weeks before to study such as leukotriene receptor antagonist , theophylline, antihistamine, COX inhibitors; 4)Receiving systemic corticosteroid within 2 weeks before the first visit; 5) Receiving monoclonal anti-IgE or omalizumab within 6 months before the first visit; 6) Underlying chronic disease such as chronic obstructive pulmonary disease, pulmonary fibrosis , bronchiectasis , coronary disease , ischemic or hemorrhagic stroke , chronic kidney disease(GFR<50 mL/min) , chronic liver disease (AST and/or ALT and/or bilirubin and/or alkaline phosphatase and/or GGT more than 1.5 times of upper normal limit; 7) Allergy to compound of Phlai; 8) Patient with pregnancy or lactation; 9)Conditions or diseases could possibly influence the results of the study as judged by the investigator.

发起方

Government Pharmaceutical Organization Thailand